Circulating Biomarkers in Malignant Melanoma

被引：32

作者：

Alegre, Estibaliz ^{[1
]}

Sammamed, Miguel ^{[2
,3
]}

Fernandez-Landazuri, Sara ^{[1
]}

Zubiri, Leyre ^{[3
]}

Gonzalez, Alvaro ^{[1
]}

机构：

[1] Univ Clin Navarra, Biochem Lab, Pamplona, Spain

[2] Univ Navarra, CIMA, Pamplona, Spain

[3] Univ Clin Navarra, Dept Oncol, Pamplona, Spain

来源：

ADVANCES IN CLINICAL CHEMISTRY, VOL 69 | 2015年 / 69卷

关键词：

POLYMERASE-CHAIN-REACTION; METASTATIC UVEAL MELANOMA; TYROSINASE MESSENGER-RNA; ENDOTHELIAL GROWTH-FACTOR; AMERICAN-JOINT-COMMITTEE; STAGE-III MELANOMA; PATIENTS RECEIVING BIOCHEMOTHERAPY; RELIABLE TUMOR-MARKER; BRAF-MUTATED MELANOMA; LONG-TERM SURVIVAL;

D O I：

10.1016/bs.acc.2014.12.002

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

100118 [医学信息学]; 100208 [临床检验诊断学];

摘要：

Melanoma is an aggressive tumor with increasing incidence worldwide. Biomarkers are valuable tools to minimize the cost and improve efficacy of treatment of this deadly disease. Serological markers have not widely been introduced in routine clinical practice due to their insufficient diagnostic sensitivity and specificity. It is likely that the lack of objective responses with traditional treatment hinder biomarker research and development in melanoma. Recently, new drugs and therapies have, however, emerged in advanced melanoma with noticeable objective response ratio and survival. In this new scenario, serological tumor markers should be revisited. In addition, other potential circulating biomarkers such as cell-free DNA, exosomes, microRNA, and circulating tumor cells have also been identified. In this review, we summarize classical and emerging tumor markers and discuss their possible roles in emerging therapeutics.

引用

页码：47 / 89

页数：43

共 239 条

[1]

Abraha HD, 1997, BRIT J DERMATOL, V137, P381, DOI 10.1111/j.1365-2133.1997.tb03742.x

[2]

S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma [J].